caa a22 4500 445355786 CHVBK 20180317142859.0 cr unu---uuuuu 170323e20111201xx s 000 0 eng 10.1007/s10072-011-0612-6 doi (NATIONALLICENCE)springer-10.1007/s10072-011-0612-6 Safety and tolerability of dapsone for the treatment of patients with drug-resistant, partial-onset seizures: an open-label trial [Elektronische Daten] [Mario López-Gómez, Teresa Corona, Araceli Diaz-Ruiz, Camilo Ríos] Dapsone has shown anti-convulsive properties in animal models of epilepsy. In the present study, we tested the safety and tolerability of dapsone as adjunctive therapy in adult patients with drug-resistant partial-onset seizures. Twenty-two adult patients with drug-resistant partial-onset seizures were included. After a 3-month baseline period, patients received dapsone 100mg per day, for a 3-month evaluation period. Plasma concentrations of anti-epileptic drugs (AEDs) did not significantly change during the study. No alteration of mean clinical laboratory values was observed. The reported adverse events were: mild methemoglobinemia (50%), headache (31.8%), paleness (27.3%) and somnolence (4.5%).Sixteen of 22 patients reduced their seizure frequency in more than 50% as a result of dapsone treatment. Three subjects remained seizure-free during the entire dapsone treatment period. This open-label study of adjunctive dapsone therapy at 100mg/day suggests that dapsone is safe, and well-tolerated in adults with drug-resistant partial-onset seizures. Springer-Verlag, 2011 Dapsone nationallicence Drug-resistant epilepsy nationallicence Epilepsy treatment nationallicence Partial-onset epilepsy nationallicence López-Gómez Mario Neurology Division, National Institute of Neurology and Neurosurgery, Mexico City, Mexico aut Corona Teresa Clinical Laboratory of Neurodegenerative Diseases, National Institute of Neurology and Neurosurgery, Mexico City, Mexico aut Diaz-Ruiz Araceli Neurochemistry Department, National Institute of Neurology and Neurosurgery, Ave. Insurgentes Sur No. 3877, 14269, Mexico City, DF, Mexico aut Ríos Camilo Neurochemistry Department, National Institute of Neurology and Neurosurgery, Ave. Insurgentes Sur No. 3877, 14269, Mexico City, DF, Mexico aut Neurological Sciences Springer Milan 32/6(2011-12-01), 1063-1067 1590-1874 32:6<1063 2011 32 10072 https://doi.org/10.1007/s10072-011-0612-6 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/s10072-011-0612-6 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- López-Gómez Mario Neurology Division, National Institute of Neurology and Neurosurgery, Mexico City, Mexico aut NATIONALLICENCE 700 1- Corona Teresa Clinical Laboratory of Neurodegenerative Diseases, National Institute of Neurology and Neurosurgery, Mexico City, Mexico aut NATIONALLICENCE 700 1- Diaz-Ruiz Araceli Neurochemistry Department, National Institute of Neurology and Neurosurgery, Ave. Insurgentes Sur No. 3877, 14269, Mexico City, DF, Mexico aut NATIONALLICENCE 700 1- Ríos Camilo Neurochemistry Department, National Institute of Neurology and Neurosurgery, Ave. Insurgentes Sur No. 3877, 14269, Mexico City, DF, Mexico aut NATIONALLICENCE 773 0- Neurological Sciences Springer Milan 32/6(2011-12-01), 1063-1067 1590-1874 32:6<1063 2011 32 10072 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer